FDA Vape Penalties Ruled Unconstitutional: What It Means

On June 30, 2026, the U.S. Court of Appeals for the Fifth Circuit handed FDA's tobacco enforcement program its most serious setback to date. In Texas Tobacco Barn, LLC v. HHS, a divided panel vacated a civil money penalty (CMP) the agency had imposed on a retailer for selling e-cigarette products without premarket authorization, holding that FDA's in-house penalty proceeding violated the retailer's Seventh Amendment right to a jury trial.

It is the first time a federal appeals court has struck down FDA's tobacco penalty authority. The relief itself is narrow — one penalty, one retailer — but the precedent now binds federal courts across Texas, Louisiana, and Mississippi, and it lands in the middle of an already turbulent year for vape regulation. Here is what happened, and what it actually means for e-liquid brands, distributors, and wholesale buyers.

What the Fifth Circuit Decided

The 2-1 majority built its ruling on SEC v. Jarkesy, the Supreme Court's 2024 decision holding that when a federal agency seeks civil penalties for claims that resemble traditional common-law actions, the defendant is entitled to a jury trial in a real court — not a hearing before the agency's own administrative judges.

FDA argued its tobacco penalties fall under the "public rights" exception to that rule. The majority disagreed. It found that FDA's claim — that selling unauthorized vape products renders them "adulterated" and "misbranded" under the Food, Drug, and Cosmetic Act — closely tracks historical common-law actions against merchants who sold unwholesome food and drink or misrepresented their goods. Because the claim resembles a common-law action and no exception applies, the Seventh Amendment requires a jury, and the administrative penalty could not stand.

The dissent saw it differently: the retailer was never accused of selling a harmful product or deceiving anyone — only of skipping FDA's premarket authorization process, something with no common-law counterpart. That disagreement over how closely a modern statute must resemble an old cause of action is precisely the kind of question the Supreme Court may ultimately have to settle.

How We Got Here

Civil money penalties have been one of FDA's workhorse tools against unauthorized vape products. The typical sequence runs from a warning letter to a CMP complaint adjudicated inside the agency. After Jarkesy, two federal district courts in Texas had already declared that scheme unconstitutional, but those rulings applied only to the parties in front of them. Texas Tobacco Barn converts that trickle into binding circuit precedent — and two more challenges (the Wulferic and Vaping Dragon cases) are stayed at the Fifth Circuit, with a similar case pending before the D.C. Circuit. If the circuits split, Supreme Court review becomes far more likely.

There are already signs of a shift in practice. Attorneys at Hyman, Phelps & McNamara, the FDA law firm that has tracked this litigation closely, report finding no new FDA penalty complaints for unauthorized e-cigarette sales since mid-December 2025 — even as underage-sale enforcement continues apace. Whether that reflects litigation risk or changing enforcement priorities, the agency's posture toward unauthorized products appears to be in transition.

Not a Green Light for Unauthorized Products

The most important thing this ruling does not do: it does not touch the premarket authorization requirement itself. Selling an ENDS product without an FDA marketing order remains illegal under federal law. What changed is one enforcement mechanism, in one circuit, pending likely further appeals.

FDA retains plenty of other tools — product seizures, injunctions, and import refusals among them — and it can still pursue civil penalties the constitutional way, before a jury in federal court. The agency may also seek rehearing en banc or take the case to the Supreme Court. And while federal penalty mechanics get sorted out, states have kept moving in the opposite direction, with product registry laws and directory enforcement that can pull products off shelves regardless of what happens in federal court.

What This Means for Brands and Distributors

For B2B operators, the practical read is caution, not celebration. Retail-level penalty exposure may be paused inside the Fifth Circuit, but distribution-level risk — seizures, import alerts, state directory delistings, and private litigation — is unchanged. Buyers and distributors evaluating product lines should keep asking the same questions: Is the product's regulatory status documented? Is the manufacturer's paper trail complete? Can the supplier demonstrate consistent, controlled production?

If anything, an enforcement landscape that is increasingly decided in courtrooms raises the value of documentation. When regulatory outcomes turn on evidence, businesses with clean records — standardized formulations, batch-level production data, supplier traceability — are in a fundamentally stronger position than those without.

Built for a Compliance-First Market

Nova Manufacturing is a US-based e-liquid contract manufacturer built for exactly this environment: standardized formulations, complete batch documentation, and GMP-quality production for brands, distributors, and wholesale buyers who need products they can stand behind. If you're re-evaluating your supply chain in light of the shifting enforcement picture, get in touch — we're happy to talk through what compliant, well-documented manufacturing looks like.